Log in

LON:SBTXSkinbiotherapeutics Share Price, Forecast & News

GBX 26.50
+1.75 (+7.07 %)
(As of 08/12/2020 03:24 AM ET)
Today's Range
Now: GBX 26.50
50-Day Range
MA: GBX 19.51
52-Week Range
Now: GBX 26.50
Volume913,934 shs
Average Volume261,826 shs
Market Capitalization£33.94 million
P/E RatioN/A
Dividend YieldN/A
SkinBioTherapeutics plc, a life science company, engages in the research and development of lysates derived from the human microbiome on skin. It is developing pre-clinical product application, SkinBiotix, a cosmetic cream for skin health, as well as for applications in infection control and eczema. The company was formerly known as Skinbiotix Ltd. SkinBioTherapeutics plc was founded in 2016 and is based in Macclesfield, the United Kingdom.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.44 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesN/A
Cash FlowGBX 2.03 per share
Book ValueGBX 2.40 per share



Market Cap£33.94 million
Next Earnings DateN/A
OptionableNot Optionable
GBX 26.50
+1.75 (+7.07 %)
(As of 08/12/2020 03:24 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SBTX News and Ratings via Email

Sign-up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Skinbiotherapeutics (LON:SBTX) Frequently Asked Questions

How has Skinbiotherapeutics' stock been impacted by COVID-19 (Coronavirus)?

Skinbiotherapeutics' stock was trading at GBX 8.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SBTX shares have increased by 211.8% and is now trading at GBX 26.50.
View which stocks have been most impacted by Coronavirus

How were Skinbiotherapeutics' earnings last quarter?

Skinbiotherapeutics PLC (LON:SBTX) announced its earnings results on Tuesday, March, 3rd. The company reported ($0.64) EPS for the quarter.
View Skinbiotherapeutics' earnings history

Has Skinbiotherapeutics been receiving favorable news coverage?

News headlines about SBTX stock have trended negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Skinbiotherapeutics earned a news sentiment score of -2.6 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future.
View the latest news about Skinbiotherapeutics

Who are some of Skinbiotherapeutics' key competitors?

What other stocks do shareholders of Skinbiotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Skinbiotherapeutics investors own include Anglo Pacific Group (APF), Avacta Group (AVCT), Inspired Energy (INSE), OptiBiotix Health (OPTI), LB-Shell (LBP), Namibian Resources (AAOG), Big Sofa Technologies Group (BST), Concepta (CPT), Fresnillo (FRES) and Shield Therapeutics (STX).

Who are Skinbiotherapeutics' key executives?

Skinbiotherapeutics' management team includes the following people:
  • Dr. Catherine O'Neill, CEO, Chief Scientific Officer & Director
  • Mr. Douglas John Quinn, CFO, Company Sec. & Director
  • Mr. Stuart John Ashman, Exec. Director (Age 52)

What is Skinbiotherapeutics' stock symbol?

Skinbiotherapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SBTX."

How do I buy shares of Skinbiotherapeutics?

Shares of SBTX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Skinbiotherapeutics' stock price today?

One share of SBTX stock can currently be purchased for approximately GBX 26.50.

How big of a company is Skinbiotherapeutics?

Skinbiotherapeutics has a market capitalization of £33.94 million. Skinbiotherapeutics employs 6 workers across the globe.

What is Skinbiotherapeutics' official website?

The official website for Skinbiotherapeutics is www.skinbiotherapeutics.com.

How can I contact Skinbiotherapeutics?

Skinbiotherapeutics' mailing address is 15 1 Silk House, Park Green, MACCLESFIELD, SK11 7QJ, United Kingdom. The company can be reached via phone at +44-161-4682760.

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.